Jones Financial Companies Lllp Purchases 14,948 Shares of CRISPR Therapeutics AG $CRSP

Jones Financial Companies Lllp lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 50.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 44,715 shares of the company’s stock after purchasing an additional 14,948 shares during the period. Jones Financial Companies Lllp’s holdings in CRISPR Therapeutics were worth $2,758,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CRSP. Mirae Asset Global Investments Co. Ltd. raised its position in CRISPR Therapeutics by 5.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after purchasing an additional 180 shares during the last quarter. IFP Advisors Inc increased its stake in shares of CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after buying an additional 181 shares during the period. Cerity Partners LLC raised its holdings in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after buying an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp boosted its position in CRISPR Therapeutics by 3.0% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after buying an additional 200 shares during the period. Finally, Ipswich Investment Management Co. Inc. boosted its position in CRISPR Therapeutics by 0.9% during the 3rd quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company’s stock worth $1,633,000 after buying an additional 230 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on CRSP shares. Wedbush decreased their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, November 5th. Wells Fargo & Company set a $75.00 price objective on CRISPR Therapeutics in a report on Monday, October 13th. Chardan Capital lowered their target price on CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating for the company in a research report on Wednesday, November 26th. Robert W. Baird reduced their price target on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Finally, Royal Bank Of Canada raised their price objective on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 11th. Twelve analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $67.85.

CRISPR Therapeutics Trading Up 6.2%

Shares of CRSP opened at $48.74 on Monday. The firm’s fifty day simple moving average is $54.74 and its two-hundred day simple moving average is $57.79. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48. The stock has a market capitalization of $4.64 billion, a P/E ratio of -8.72 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The firm had revenue of $0.89 million during the quarter, compared to analyst estimates of $8.74 million. As a group, research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the sale, the chief executive officer directly owned 134,201 shares in the company, valued at approximately $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.